Sanofi (SNY)
(Delayed Data from NSDQ)
$53.10 USD
+1.90 (3.71%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $53.09 -0.01 (-0.02%) 7:30 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$53.10 USD
+1.90 (3.71%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $53.09 -0.01 (-0.02%) 7:30 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Zacks News
EMA Accepts Regeneron/Sanofi's application for Dupixent
by Zacks Equity Research
Regeneron and partner Sanofi's application for the label expansion of Dupixent has been accepted by the regulatory body in Europe. The application is also under review in the United States.
3 Sell-Rated Drug Stocks Investors Should Avoid for Now
by Zacks Equity Research
Despite a fairly upbeat performance of the pharma and biotech sector, caution has to be exercised before choosing a stock for investment as a few drug companies are struggling to revive business.
4 Top-Ranked Drug/Biotech Stocks to Buy as Q1 Nears End
by Kinjel Shah
The first quarter of 2018 is drawing to a close. With the outlook optimistic for the rest of the year, we highlight four drug/biotech stocks worth buying
Amgen's Repatha Gains CHMP Nod to Include Outcomes Data
by Zacks Equity Research
Amgen (AMGN) gets CHMP's positive opinion to incorporate a new indication into the European label of its PCSK9 inhibitor, Repatha.
Immune Design Poised on Progress of Pipeline Candidates
by Zacks Equity Research
Development of key pipeline candidates CMB305 and G100 is likely to keep Immune Design (IMDZ) on a growth trajectory.
Is Sanofi (SNY) a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if Sanofi (SNY) stock is a good choice for value-oriented investors right now from multiple angles.
The Zacks Analyst Blog Highlights: AT&T, Goldman Sachs, Sanofi, General Mills and Discovery
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AT&T, Goldman Sachs, Sanofi, General Mills and Discovery
Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q4
by Zacks Equity Research
Immune Design (IMDZ) reports narrower-than-expected loss in fourth quarter 2017 results and updates data for its pipeline candidates.
Diabetes Devices Market on a Tear: 3 Stocks for Solid Returns
by Sweta Jaiswal
Consider these three stocks in the rapidly-growing diabetes devices market for grand returns.
Top Research Report for AT&T, Goldman Sachs & Sanofi
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including AT&T (T), Goldman Sachs (GS) and Sanofi (SNY).
Biotech Stock Roundup: REGN Cuts Praluent Price, OREX to File for Bankruptcy
by Zacks Equity Research
The biotech sector was in focus last week with key news - Orexigen going bankrupt, Biogen acquires asset from Pfizer, Regeneron cuts Praluent price among others.
Bull of the Day: Regeneron (REGN)
by Kevin Cook
Key pharma franchises in a bustling pipeline have shares looking attractive again at 17X and 15% EPS growth
3 Biotech Stocks With Rising Earnings Estimates Post Q4
by Zacks Equity Research
The biotech industry performed reasonably well in Q4. Hence, it is a good idea to select stocks from the sector which saw positive estimate revisions post Q4 earnings release.
Regeneron and Sanofi Announce Positive Data on Praluent
by Zacks Equity Research
Regeneron (REGN) & Sanofi's Praluent achieves the primary endpoint in the ODYSSEY OUTCOMES trial as the drug reduces the overall risk of MACE by 15%.
Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck
by Zacks Equity Research
Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck
Biotech Stock Round Up: Regeneron Submits sBLA, Biogen to Withdraw Zinbryta
by Zacks Equity Research
The biotech sector was in focus last week with these stories - FDA's acceptance of Regeneron's Dupixent's application for asthma, Biogen and partner AbbVie's decision to withdraw multiple sclerosis drug among others.
Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck
by Zacks Equity Research
Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck
FDA Accepts Regeneron/Sanofi's Dupixent sBLA for Asthma
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi announced that the FDA has accepted the companies' sBLA for Dupixent for asthma with a target date of Oct 20, 2018.
4 Buy-Ranked Large Cap Pharma Stocks to Boost Your Portfolio
by Zacks Equity Research
Though the large-cap pharma sector struggled a little after a strong start in 2018, it is largely expected to rebound as the year progresses.
Biotech Crushing the Market: Best ETFs & Stocks YTD
by Sweta Killa
The recent developments are fueling growth in the biotech companies, leading to a rally in their share prices and impressive levels of momentum in biotech ETFs.
Emergent (EBS) Q4 Earnings Beat Estimates, 2018 View Solid
by Zacks Equity Research
Emergent's (EBS) earnings and revenues beat estimates in Q4. The top line also improves year over year on higher product sales.
BioMarin (BMRN) Q4 Loss Wider Than Expected, Sales Beat
by Zacks Equity Research
BioMarin (BMRN) reports wider-than-expected loss in the fourth quarter of 2017 but beat estimates for sales on higher product revenues.
Merck to Buy Australian Firm to Boost Immunotherapy Pipeline
by Zacks Equity Research
Merck (MRK) to buy Australian oncolytic immunotherapies maker Viralytics Limited to strengthen its presence in the fast growing immuno-oncology market.
The Zacks Analyst Blog Highlights: ExxonMobil, Caterpillar, Union Pacific, Alexion and Sanofi
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ExxonMobil, Caterpillar, Union Pacific, Alexion and Sanofi
Top Research Reports for ExxonMobil, Caterpillar & Union Pacific
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including ExxonMobil (XOM), Caterpillar (CAT) and Union Pacific (UNP).